Skip to content

Health Improvement Project - Providence

Mindfulness Training to Improve ART Adherence and Reduce Risk Behavior Among Persons Living With HIV

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02886234
Acronym
HIP
Enrollment
50
Registered
2016-09-01
Start date
2016-08-31
Completion date
2018-08-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV, Mindfulness, Adherence behaviors, Stress, Depression

Brief summary

This study will investigate whether phone-delivered mindfulness training is feasible and acceptable for persons living with HIV and whether it may help them improve adherence to medications and reduce risky sexual behaviors.

Detailed description

Two-thirds of people living with HIV show sub-optimal adherence to antiretroviral therapy (ART) and one-third engages in risky sex. Both non-adherence and risky sex have been associated with emotional distress and impulsivity. In this trial, the investigators will examine the utility of phone-delivered mindfulness training (MT) for people living with HIV. The primary outcomes comprise feasibility and acceptability of phone-delivery; secondary outcomes are estimates of efficacy of MT on adherence to ART and safer sexual practices as well as on their hypothesized antecedents. Fifty participants will be enrolled in this parallel-group randomized clinical trial (RCT). Outpatients recruited from an HIV treatment clinic will be randomized (1:1 ratio) to either MT or to health coaching intervention; both interventions will be administered during 8 weekly phone calls. ART adherence (self-reported measure and unannounced phone pill counts), sexual behavior (self-reports and biomarkers), mindfulness, depression, stress, and impulsivity will be measured at baseline, post-intervention, and 3 months post-intervention.

Interventions

Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.

The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
The Miriam Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* HIV infection * Sub-optimal adherence to ART (Less than always taking ART medication and/or viral load \> 20 copies/mL); * Psychological distress (PHQ-4 score ≥ 2); * Recent risky sexual behavior (any unprotected sex OR \> 1 sexual partner over the past 6 months) * Access to a telephone or cell phone

Exclusion criteria

* Unwilling or unable to provide informed consent * Cognitive impairment * Non-English speaking * Low literacy (i.e., reporting they often or always need someone to read instructions, pamphlets, or other written material from a doctor or pharmacy to them * Enrolled in another behavioral trials * Prior formal mindfulness training or have practiced of mindfulness or related mind-body techniques in the previous year * Severe hearing impairment not allowing phone delivery * Suicidal ideation * Planning to move out of the area within the study period * Clinic provider advising against recruitment in the study.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Interventionpost-intervention, 9 to 10 weeks after baselineFeasibility - as indicated by the number of patients attending at least 50% of sessions

Secondary

MeasureTime frameDescription
Antiretroviral Medication AdherenceBaseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baselineSelf-reported number of missed days of medication
Self-reported Sexual Risk BehaviorBaseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baselineSelf-reported risky sexual behavior as indicated by the percentage of episodes of condom protected sexual intercourse Higher values are better outcome
Five Facet Mindfulness QuestionnaireBaseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baselineFive Facet of Mindfulness Questionnaire (15 items; short form) Construct = Mindfulness Minimum total scale score = 15 Maximum total scale score = 75 Scoring: sum across all 15 items Higher scores represent a better outcome
Acceptability of the Interventionpost-intervention, 9 to 10 weeks after baselineNumber of patients reporting very satisfied or mostly satisfied with their intervention
Barratt Impulsiveness ScaleBaseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baselineBarratt Impulsiveness Scale (short form, 8 items) Construct = Impulsivity Minimum total scale score = 8 Maximum total scale score = 32 Scoring: reverse score items 1, 4, 5, 6, and then sum across all 8 items Higher scores represent a worse outcome
Patient Health QuestionnaireBaseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baselinePatient Health Questionnaire (9 item version) Construct measured = depression Minimum total scale score = 0 Maximum total scale score = 27 Scoring: sum across all 9 items Higher scores represent a worse outcome
Perceived Stress ScaleBaseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baselinePerceived Stress Scale (4-item version) Construct = perceived stress Minimum total scale score = 0 Maximum total scale score = 16 Scoring: reverse score items 2 and 3, then sum across all 4 items Higher scores represent a worse outcome

Countries

United States

Participant flow

Pre-assignment details

Prior to being randomized, patients had to complete all baseline activities, which included two months of counting to establish a baseline adherence measure. During this interval, 6 patients withdrew from the study. Thus, 44 patients were randomized (24 to health coaching arm, and 20 to the mindfulness training arm).

Participants by arm

ArmCount
Mindfulness Training (MT)
Eight, 30-minute phone delivered MT sessions once a week for 8 weeks Mindfulness Training (MT): Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
20
Health Coaching (HC)
Eight, 30-minute phone delivered HC sessions once a week for 8 weeks Health Coaching (HC): The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
22
Total42

Baseline characteristics

CharacteristicMindfulness Training (MT)TotalHealth Coaching (HC)
Age, Continuous46.4 years
STANDARD_DEVIATION 11.7
47.5 years
STANDARD_DEVIATION 11.2
48.5 years
STANDARD_DEVIATION 11
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants11 Participants6 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
15 Participants31 Participants16 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants4 Participants2 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
4 Participants11 Participants7 Participants
Race (NIH/OMB)
More than one race
3 Participants8 Participants5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants1 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants18 Participants8 Participants
Region of Enrollment
United States
20 participants42 participants22 participants
Sex: Female, Male
Female
9 Participants20 Participants11 Participants
Sex: Female, Male
Male
11 Participants22 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 200 / 22
other
Total, other adverse events
0 / 200 / 22
serious
Total, serious adverse events
0 / 200 / 22

Outcome results

Primary

Feasibility of Intervention

Feasibility - as indicated by the number of patients attending at least 50% of sessions

Time frame: post-intervention, 9 to 10 weeks after baseline

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Mindfulness Training (MT)Feasibility of Intervention11 Participants
Health Coaching (HC)Feasibility of Intervention19 Participants
Secondary

Acceptability of the Intervention

Number of patients reporting very satisfied or mostly satisfied with their intervention

Time frame: post-intervention, 9 to 10 weeks after baseline

Population: 3 participants in the MT arm did not complete the acceptability rating at the post-intervention assessment

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Mindfulness Training (MT)Acceptability of the Intervention15 Participants
Health Coaching (HC)Acceptability of the Intervention19 Participants
Secondary

Antiretroviral Medication Adherence

Self-reported number of missed days of medication

Time frame: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness Training (MT)Antiretroviral Medication AdherenceBaseline4.20 daysStandard Deviation 7.02
Mindfulness Training (MT)Antiretroviral Medication AdherencePost-Intervention3.41 daysStandard Deviation 6.57
Mindfulness Training (MT)Antiretroviral Medication Adherence3-month Follow-up2.70 daysStandard Deviation 3.53
Health Coaching (HC)Antiretroviral Medication AdherenceBaseline1.95 daysStandard Deviation 3.15
Health Coaching (HC)Antiretroviral Medication AdherencePost-Intervention1.64 daysStandard Deviation 3.3
Health Coaching (HC)Antiretroviral Medication Adherence3-month Follow-up1.45 daysStandard Deviation 1.99
Secondary

Barratt Impulsiveness Scale

Barratt Impulsiveness Scale (short form, 8 items) Construct = Impulsivity Minimum total scale score = 8 Maximum total scale score = 32 Scoring: reverse score items 1, 4, 5, 6, and then sum across all 8 items Higher scores represent a worse outcome

Time frame: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness Training (MT)Barratt Impulsiveness Scalebaseline18.15 score on a scaleStandard Deviation 3.76
Mindfulness Training (MT)Barratt Impulsiveness Scalepost-intervention17.76 score on a scaleStandard Deviation 4.31
Mindfulness Training (MT)Barratt Impulsiveness Scale3-month Follow-up16.05 score on a scaleStandard Deviation 4.07
Health Coaching (HC)Barratt Impulsiveness Scalebaseline17.50 score on a scaleStandard Deviation 4.36
Health Coaching (HC)Barratt Impulsiveness Scalepost-intervention15.68 score on a scaleStandard Deviation 3.4
Health Coaching (HC)Barratt Impulsiveness Scale3-month Follow-up16.50 score on a scaleStandard Deviation 4.42
Secondary

Five Facet Mindfulness Questionnaire

Five Facet of Mindfulness Questionnaire (15 items; short form) Construct = Mindfulness Minimum total scale score = 15 Maximum total scale score = 75 Scoring: sum across all 15 items Higher scores represent a better outcome

Time frame: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness Training (MT)Five Facet Mindfulness QuestionnairePost-Intervention53.06 score on a scaleStandard Deviation 10.32
Mindfulness Training (MT)Five Facet Mindfulness QuestionnaireBaseline47.70 score on a scaleStandard Deviation 7.09
Mindfulness Training (MT)Five Facet Mindfulness Questionnaire3-month Follow-up53.05 score on a scaleStandard Deviation 7.49
Health Coaching (HC)Five Facet Mindfulness QuestionnairePost-Intervention52.73 score on a scaleStandard Deviation 8.98
Health Coaching (HC)Five Facet Mindfulness QuestionnaireBaseline49.09 score on a scaleStandard Deviation 8.09
Health Coaching (HC)Five Facet Mindfulness Questionnaire3-month Follow-up52.18 score on a scaleStandard Deviation 7.84
Secondary

Patient Health Questionnaire

Patient Health Questionnaire (9 item version) Construct measured = depression Minimum total scale score = 0 Maximum total scale score = 27 Scoring: sum across all 9 items Higher scores represent a worse outcome

Time frame: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness Training (MT)Patient Health QuestionnaireBaseline9.80 score on a scaleStandard Deviation 6.58
Mindfulness Training (MT)Patient Health QuestionnairePost-Intervention8.82 score on a scaleStandard Deviation 6.66
Mindfulness Training (MT)Patient Health Questionnaire3-month Follow-up6.90 score on a scaleStandard Deviation 5.23
Health Coaching (HC)Patient Health QuestionnaireBaseline8.55 score on a scaleStandard Deviation 5.54
Health Coaching (HC)Patient Health QuestionnairePost-Intervention5.68 score on a scaleStandard Deviation 4.82
Health Coaching (HC)Patient Health Questionnaire3-month Follow-up5.18 score on a scaleStandard Deviation 3.72
Secondary

Perceived Stress Scale

Perceived Stress Scale (4-item version) Construct = perceived stress Minimum total scale score = 0 Maximum total scale score = 16 Scoring: reverse score items 2 and 3, then sum across all 4 items Higher scores represent a worse outcome

Time frame: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness Training (MT)Perceived Stress ScaleBaseline6.90 score on a scaleStandard Deviation 4.09
Mindfulness Training (MT)Perceived Stress Scalepost-Intervention6.06 score on a scaleStandard Deviation 3.58
Mindfulness Training (MT)Perceived Stress Scale3-month Follow-up5.80 score on a scaleStandard Deviation 3.71
Health Coaching (HC)Perceived Stress ScaleBaseline5.86 score on a scaleStandard Deviation 3.01
Health Coaching (HC)Perceived Stress Scalepost-Intervention5.64 score on a scaleStandard Deviation 2.75
Health Coaching (HC)Perceived Stress Scale3-month Follow-up5.73 score on a scaleStandard Deviation 3.28
Secondary

Self-reported Sexual Risk Behavior

Self-reported risky sexual behavior as indicated by the percentage of episodes of condom protected sexual intercourse Higher values are better outcome

Time frame: Baseline; post-intervention, 9 to 10 weeks after baseline; follow-up, 21 to 22 weeks after baseline

ArmMeasureGroupValue (MEAN)Dispersion
Mindfulness Training (MT)Self-reported Sexual Risk BehaviorBaseline57 percentage of sexual events condom usedStandard Deviation 44
Mindfulness Training (MT)Self-reported Sexual Risk Behaviorpost-intervention100 percentage of sexual events condom usedStandard Deviation 236
Mindfulness Training (MT)Self-reported Sexual Risk Behavior3-month Follow-up71 percentage of sexual events condom usedStandard Deviation 49
Health Coaching (HC)Self-reported Sexual Risk BehaviorBaseline32 percentage of sexual events condom usedStandard Deviation 44
Health Coaching (HC)Self-reported Sexual Risk Behaviorpost-intervention49 percentage of sexual events condom usedStandard Deviation 71
Health Coaching (HC)Self-reported Sexual Risk Behavior3-month Follow-up43 percentage of sexual events condom usedStandard Deviation 48

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026